Mid-Day Market Update: Silver Surges 3%; Galera Therapeutics Shares Plunge

Midway through trading Tuesday, the Dow traded up 0.47% to 35,423.05 while the NASDAQ rose 0.59% to 15,110.79. The S&P also rose, gaining 0.61% to 4,513.69.

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 45,908,210 cases with around 746,500 deaths. India confirmed a total of at least 34,094,370 cases and 452,480 deaths, while Brazil reported over 21,651,910 COVID-19 cases with 603,520 deaths. In total, there were at least 242,021,450 cases of COVID-19 worldwide with more than 4,923,690 deaths, according to data compiled by Johns Hopkins University.


Leading and Lagging Sectors


Health care shares gained by 1.5% on Tuesday. Meanwhile, top gainers in the sector included HCW Biologics Inc. HCWB, up 20% and Harmony Biosciences Holdings, Inc. HRMY up 15%.


In trading on Tuesday, consumer staples shares fell 0.6%.


Top Headline


Johnson & Johnson JNJ reported better-than-expected earnings for its third quarter and raised its FY21 forecast.

Johnson & Johnson reported quarterly earnings of $2.60 per share, beating analysts’ estimates of $2.36 per share. The company reported quarterly revenue of $23.34 billion, versus analysts’ estimates of $23.74 billion.

Johnson & Johnson raised FY21 guidance to overall sales of $94.1 billion - $94.6 billion ($93.8 billion - $94.6 billion previously), including $2.5 billion from COVID-19 vaccine sales. It expects adjusted EPS of $9.77-$9.82, as against the earlier outlook of $9.60 - $9.70, higher than the consensus of $9.66.


Equities Trading UP


HCW Biologics Inc. HCWB shares shot up 20% to $3.40.

Shares of Harmony Biosciences Holdings, Inc. HRMY got a boost, shooting 15% to $43.93 after it was announced the company will replace Retail Properties of America in the S&P SmallCap 600.

InflaRx N.V. IFRX shares were also up, gaining 11% to $2.6913 after the company announced it was awarded an up to roughly $50.7 million grant by the German government to advance the development of vilobelimab for the treatment of severe COVID-19.

Check out these big movers of the day


Equities Trading DOWN

Galera Therapeutics, Inc. GRTX shares tumbled 68% to $2.34 in reaction to disappointing data from the Phase 3 ROMAN trial of avasopasem manganese in severe oral mucositis (SOM) patients with locally advanced head and neck cancer (HNC) undergoing standard-of-care radiotherapy.


Shares of Atea Pharmaceuticals, Inc. AVIR were down 62% to $15.35 after the company reported data from the Phase 2 MOONSONG trial of AT-527 in the outpatient setting in patients with mild or moderate COVID-19. The trial did not meet the primary endpoint of clear reduction in SARS-CoV-2 viral load in the overall population compared to placebo.


EverQuote, Inc. EVER was down, falling 15% to $14.81 after the company cut third-quarter sales guidance below estimates.


Commodities

In commodity news, oil traded up 0.9% to $83.15, while gold traded up 0.3% to $1,771.70.


Silver traded up 3% Tuesday to $23.96 while copper fell 0.3% to $4.7135.


Euro zone

European shares were mostly higher today. The eurozone’s STOXX 600 gained 0.36%, the Spanish Ibex Index rose 0.63% and the German DAX 30 gained 0.33%. Meanwhile, the London’s FTSE 100 rose 0.22%, French CAC 40 slipped 0.05% and Italy’s FTSE MIB gained 0.43%.

Spanish trade deficit widened to EUR 3.87 billion in August from a EUR 1.73 billion gap in the year-ago month.


Economics


Housing starts dropped by 1.6% to an annual rate of 1.555 million in September, while building permits fell 7.7% to an annual rate of 1.589 million.


Federal Reserve Bank of Atlanta President Raphael Bostic is set to speak at 1:00 p.m. ET.

Check out the full economic calendar here

Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPenny StocksEurozoneCommoditiesSmall CapGlobalIntraday UpdateMarketsMid-Day Market Update
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...